{"entity":{"id":"nct03228667","kind":"trial","name":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","aka":[],"tldr":"A phase 2 trial of Nogapendekin alfa inbakicept, Pembrolizumab, Nivolumab in non-small-cell lung cancer and small-cell lung cancer, run by ImmunityBio, Inc., active and no longer recruiting.","summary":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors is a phase 2 interventional study registered as NCT03228667 by ImmunityBio, Inc., with 40 participants planned, started 2018-12-11 and due to reach its primary completion in 2029-08-31. Interventions recorded: N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab. Conditions listed: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03228667","url":"https://clinicaltrials.gov/study/NCT03228667"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","head-and-neck","merkel-cell-carcinoma","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["nogapendekin-alfa","pembrolizumab","nivolumab","atezolizumab","avelumab","durvalumab"],"companies":["immunitybio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03228667","phase":"2","setting":"QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors","sponsor":"ImmunityBio, Inc.","enrolled":40,"outcomes":[]},"route":"/trials/nct03228667/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"avelumab","kind":"drug","name":"Avelumab","route":"/drugs/avelumab/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"nogapendekin-alfa","kind":"drug","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"immunitybio","kind":"company","name":"ImmunityBio","route":"/companies/immunitybio/"}]}}